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Abstract
Previously, it was shown that modulation of the immune system enhances porcine circovirus type 2 (PCV2) replication in
pigs. In the present study, the effect of the mitogen concanavalin A (ConA) on PCV2 replication was investigated. Since ConA
induces T-lymphocyte activation and initiates the production of interferon-gamma (IFN-g), a cytokine that enhances PCV2
replication in porcine epithelial and monocytic cell lines in vitro, it was examined if the effects observed with ConA were
mediated by IFN-g. In an in vitro study, ConA but not IFN-g enhanced PCV2 replication in peripheral blood mononuclear cells
(PBMC). Up to 2.08% and 0.96% of PBMC were antigen positive for PCV2 strains 1121 and Stoon-1010, respectively, and a low
virus production was observed. PCV2-infected PBMC were identified as CD4+ (40%), CD8+ (54%) and IgM+ (11%). In a
subsequent in vivo study, caesarean-derived colostrum-deprived piglets were injected with ConA or IFN-g 12 h before
inoculation and every 3 days for 9 days after inoculation with strain 1121. PCV2 was isolated from inguinal lymph node
biopsies from 10 days post-inoculation (dpi) in ConA-treated pigs and from 15 dpi in non-treated and IFN-g-treated pigs. ConA
increased PCV2 replication levels, but disease was not observed. Half of the ConA-treated and IFN-g-treated pigs showed a
delayed humoral immune response, but this delay did not result in increased PCV2 replication in these pigs. These experiments
demonstrated that ConA enhances PCV2 replication in PBMC in vitro and in lymphoid tissues in vivo.
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Porcine circovirus type 2 (PCV2) is a small, non-
enveloped, single-stranded DNA virus. It is a member
of the family of the Circoviridae and it is widespread
in wild and domestic pigs. In pig dense regions, PCV2
infects all conventional pigs after weaning. The
majority of these infections are sub-clinical. Under.
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weaning multisystemic wasting syndrome (PMWS),
a multifactorial disease that causes severe growth
retardation, weight loss and death in weaned piglets
(Segales and Domingo, 2002). PMWS is characterized
by severe lymphocytic depletion and monocytic
infiltration in lymphoid tissues and high amounts of
PCV2 are found within these lesions (Segales and
Domingo, 2002).
PCV2 lacks its own polymerases and therefore
fully depends on cellular enzymes to complete its
infectious cycle. Up till now, only 4 different viral
proteins have been described in porcine circovirus-
infected cells (Mankertz and Hillenbrand, 2002; Liu
et al., 2005), which makes PCV2 incapable of actively
modifying the immune response of its host in its own
favour, as other more complex viruses do (Tortorella
et al., 2000). Therefore, specific conditions in the host
intensively influence PCV2 replication. Co-infections
with other infectious agents such as porcine parvo-
virus (PPV) (Allan et al., 1999), porcine reproductive
and respiratory syndrome virus (PRRSV) (Allan et al.,
2000) and Mycoplasma hyopneumoniae (Opriessnig
et al., 2004) enhance PCV2 replication and exacerbate
the clinical outcome of a PCV2 infection. Injection of
immune stimulating drugs such as the soluble protein
antigen Keyhole limpet hemocyanin (KLH) in
incomplete Freund’s adjuvant (Krakowka et al.,
2001) and vaccination (Opriessnig et al., 2003)
enhance PCV2 replication as well, suggesting that
the induction of an immune response might be a key
factor in the induction of high levels of PCV2
replication. However, strategies involving immune-
stimulating drugs or vaccination have not always been
successful in enhancing PCV2 replication and PMWS
occurrence (Resendes et al., 2004).
PCV2 replication in lymphoid tissues occurs in B-
lymphocytes, T-lymphocytes, monocytes and macro-
phages (Sanchez et al., 2004). Recently, it was shown
that the plant lectin concanavalin A (ConA) is able to
induce PCV2 replication in CD3+ peripheral blood
mononuclear cells (PBMC) that have been inoculated
with PCV2 in vitro (Yu et al., 2007). Mitogen
stimulation also induces porcine parvovirus (PPV)
replication in porcine peripheral blood lymphocytes
(Paul et al., 1979) and TT virus replication in human
PBMC (Mariscal et al., 2002). PPV and TT virus are
also non-enveloped, single-stranded DNA viruses. Themitogen ConA causes predominantly T-lymphocyte
proliferation and activation (Mosmann et al., 1986),
leading to the production of lymphokines. More
specifically, ConA induces production of high con-
centrations of interferon-gamma (IFN-g) in vitro
(Verfaillie et al., 2001) and in vivo (Miyagi et al., 2004).
Recently, it was shown that interferon-alpha (IFN-
a) and especially IFN-g are able to enhance PCV2
replication in cell lines in vitro. When administered
after PCV2 inoculation, 1000 units of IFN-g/106 cells
increased the number of PCV2-infected cells in
epithelial PK-15 and monocytic 3D4/31 cells with
691% and 423%, respectively (Meerts et al., 2005b).
However, an in vivo study demonstrated that pigs with
high IFN-gmRNA expression levels in PBMC are less
susceptible to PCV2 replication (Meerts et al., 2005c).
Up till now, the effects of ConA and IFN-g on PCV2
replication in vivo are not known.
It is the aim of the present study to determine the
effects of ConA and IFN-g on PCV2 replication in
PBMC in vitro and to try to set up a model for the
reproduction of PMWS using ConA and IFN-g in vivo.2. Material and methods
2.1. Cells
PCV negative PK-15 cells were grown in minimal
essential medium (MEM) containing Earle’s salts
(Gibco, Grand Island, USA), supplemented with 5%
foetal bovine serum (FBS), 0.3 mg ml1 glutamine,
100 U ml1 penicillin, 0.1 mg ml1 streptomycin and
0.1 mg ml1 kanamycin.
PBMC were separated from blood by density
centrifugation at 750  g on Ficoll-Paque1 (Amer-
sham Pharmacia Biotech AB, Uppsala, Sweden). These
cells were maintained in RPMI1640 (Gibco) containing
10% FBS, 0.3 mg ml1 glutamine, 100 U ml1 peni-
cillin, 0.1 mg ml1 streptomycin, 0.1 mg ml1 kana-
mycin, 1% non-essential amino acids (100; Gibco)
and 1% sodium pyruvate (100 mM; Gibco). Cells were
maintained at 37 8C in the presence of 5% CO2.
2.2. Viruses
PCV2 strains 1121 and Stoon-1010 were used in
this study. The replication kinetics of these 2 strains
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myocytes and alveolar macrophages by Meerts et al.
(2005a). For in vitro use, 1121 and Stoon-1010 were at
a 29th and 19th passage level on PK-15 cells,
respectively. For in vivo inoculation, a 4th passage
on PK-15 cells of strain 1121 was used.
2.3. Concanavalin A and recombinant IFN-g
ConA was purchased from Sigma (Heidelberg,
Germany). Recombinant IFN-g (rIFN-g) was pur-
chased from R&D Systems (Abingdon, UK).
2.4. Pigs
Six 9-month-old conventional PCV2 seronegative
pigs were used as blood donors for the isolation of
PBMC.
Seventeen caesarean-derived colostrum-deprived
(CD/CD) pigs were obtained from 2 Landrace sows
and were raised in sterile conditions in individual
isolators.
2.5. In vitro experiments
2.5.1. Inoculation and treatment
After isolation, PBMC were inoculated with a dose
of 104.3 TCID50/10
6 PBMC for 1 h at 37 8C. After
inoculation, cells were washed twice, resuspended in
fresh medium and seeded in 24-well cell culture plates
(Nunc, Roskilde, Denmark) at a concentration of 106
PBMC ml1. Immediately after seeding, ConA or
rIFN-g was added at a dose of 5 mg/106 PBMC or
1000 units/106 PBMC, respectively. A dose of 5 mg
ConA/106 PBMC is commonly used to induce pro-
liferation in porcine PBMC (Verfaillie et al., 2001). A
dose of 1000 units of rIFN-g/106 cells was the most
efficient dose to increase the number of PCV2-infected
cells in PK-15 and 3D4/31 cells (Meerts et al., 2005b).
This dose was effective for stimulating PBMC in vitro,
because 24 h after treatment, a fivefold increase in
interleukin-12 levels was observed in supernatant fluids
of rIFN-g-treated PBMC when compared to non-
treated PBMC. This was measured with a commercial
ELISA for interleukin-12 (R&D Systems).
PBMC inoculated with PK-15 cell culture medium
and treated with ConA or rIFN-g were included as
negative controls.2.5.2. Fixation and stainings
At 0, 12, 24, 36, 48, 72 and 96 h post-inoculation
(hpi), PBMC and supernatant fluids were collected.
Cells were smeared onto glass slides, fixed in
methanol at 20 8C for 10 min and stored at
20 8C until use. Supernatant fluids were centrifuged
at 2900  g for 10 min and stored at 20 8C until
virus titration on PK-15 cells.
Expression kinetics of the non-structural Rep
protein and the structural capsid protein were
determined with double immunofluorescence stain-
ings using the monoclonal antibody (mAb) F210,
directed against the PCV2 Rep protein (McNeilly
et al., 2001), and biotinylated purified porcine
polyclonal antibodies (pAbs), directed against the
PCV2 capsid protein (Meerts et al., 2005a). Briefly,
fixed cell smears were air-dried at room temperature
for 10 min. Next, they were incubated with an optimal
dilution of mAb F210 in phosphate-buffered saline
(PBS). Subsequently, a 1:500 dilution of fluorescein
isothiocyanate (FITC)-labelled goat anti-mouse pAbs
(Molecular Probes, Eugene, USA) in PBS was
applied. This was followed by an optimal dilution
of biotinylated purified porcine pAbs in PBS, followed
by incubation with a 1:100 dilution of Texas Red-
labelled streptavidin (Molecular Probes) in PBS. Each
of these incubations were performed for 1 h at 37 8C.
Finally, Hoechst 33342 (Molecular Probes) was
applied at a concentration of 10 mg ml1 for 10 min
at room temperature, in order to visualize the nucleus.
Cell smears were washed three times with PBS
between the incubations. Stained cell smears were
mounted with a glycerol solution containing 1,4-
diazabicyclo(2.2.2)octane (DABCO) anti-fading
agent (Janssen Chimica, Beerse, Belgium). A LEICA
DM/RBE fluorescence microscope (Leica Microsys-
tems GmbH, Heidelberg, Germany) was used for
visualization. Expression kinetics of the Rep protein
and the capsid protein were assessed at 0, 12, 24, 36,
48, 72 and 96 hpi, by determination of nuclear and
cytoplasmic localization of PCV2 antigens in 5000
PBMC at each time point.
PCV2 positive PBMC (strain 1121) were further
characterized at 0, 36 and 72 hpi by using mAbs
directed against cell markers CD4, CD8, IgM and
SWC3, respectively. The cell marker CD4 is present
on T-helper and memory T-helper lymphocytes,
regulatory T-lymphocytes and natural interferon-alpha
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Table 1
Distribution of caesarean-derived colostrum-deprived pigs in dif-
ferent groups with specific manipulations per group
Group n PCV2 inoculation Treatment Pig numbers
A 4 Yes – 1–4
B 4 Yes ConA 5–8
C 4 Yes rIFN-g 9–12
D 3 No ConA 13–15
E 2 No rIFN-g 16–17producing cells (Pescovitz et al., 1984; Charley and
Lavenant, 1990). CD8 is present on cytotoxic and
gamma-delta T-lymphocytes, memory T-lymphocytes
and natural killer cells (Pescovitz et al., 1984;
Saalmuller et al., 1994). IgM is present on naı¨ve B-
lymphocytes, B-lymphoblasts and IgM-producing
plasma cells (Van Zaane and Hulst, 1987). SWC3 is
present on monocytes, macrophages, dendritic cells
and granulocytes (Pescovitz et al., 1984; Paillot et al.,
2001). The staining procedure was similar to the
technique described above. Cell smears were incu-
bated with optimal dilutions of mAbs against CD4,
CD8, IgM or SWC3, respectively, followed by FITC-
labelled goat anti-mouse pAbs. Thereafter, cell smears
were stained with biotin-conjugated porcine anti-
PCV2 pAbs, followed by Texas Red-labelled strepta-
vidin. On each cell smear, all PCV2 positive cells were
analyzed by fluorescence microscopy.
2.5.3. Virus titration of PBMC culture
supernatant
Tenfold dilutions of PBMC culture supernatants
were inoculated on semi-confluent monolayers of
PCV negative PK-15 cells. After 72 h of incubation,
cells were fixed in 4% paraformaldehyde in PBS.
PCV2-infected cells were detected via an immuno-
peroxidase monolayer assay (IPMA) as described by
Labarque et al. (2000).
2.5.4. Statistical analysis
The statistical significance of differences between
non-treated PBMC and ConA-treated PBMC and
between non-treated PBMC and rIFN-g-treated
PBMC was tested by applying two-sided Kruskal–
Wallis tests. Differences were considered significant
when p < 0.05. Statistical analyses were performed
using S-PLUS (S-PLUS 6.1, Insightful Corporation,
Seattle, USA, 2002).
2.6. In vivo experiments
2.6.1. Inoculation and treatment
The set up of the experiment is illustrated in
Table 1. The 17 CD/CD pigs were randomly divided
in 5 groups. At 19 days of age, all pigs from groups A
(PCV2/-), B (PCV2/ConA) and C (PCV2/rIFN-g)
were inoculated intraperitoneally and oronasally with
a total dose of 104.3 TCID50 of strain 1121. Pigs ofgroups D (-/ConA) and E (-/rIFN-g) were mock
inoculated with equal volumes of cell culture
medium. Treatment regimes with ConA or rIFN-g
were designed based on the results of a preliminary
experiment in conventional pigs. In PCV2-inoculated
PK-15 cells, addition of plasma of a ConA-treated
conventional pig or a rIFN-g-treated conventional pig
increased the number of infected cells with maximum
524% and 154%, respectively, when compared with
plasma samples from the same pigs before ConA or
rIFN-g treatment. As a result from this experiment,
pigs from groups B (PCV2/ConA) and D (-/ConA)
were injected every 3 days with ConA at a dose of
1.5 mg kg1 body weight. Half of the dose was
injected intramuscularly (IM) in the neck and the
other half was injected subcutaneously (SC) in the
region of the lower abdomen that is drained by the
inguinal lymph nodes. The first injection was
administered 12 h before PCV2 inoculation of the
pigs and repeated at 2, 5 and 8 days post-inoculation
(dpi). Pigs from groups C (PCV2/rIFN-g) and E (-/
rIFN-g) were treated at the same time points with
rIFN-g at a dose of 100,000 units (3 mg of
recombinant protein) per treatment: 50,000 units
were injected IM in the neck and 50,000 units SC in
the lower abdomen. Pigs were monitored for a period
of 21 days after PCV2 inoculation and humanly
euthanized afterwards, by intravenous injection of a
barbiturate overdose (Natriumpentobarbital 20%,
Kela, Hoogstraten, Belgium).
2.6.2. Clinical monitoring
Pigs were monitored daily for the appearance of
clinical signs that are typically associated with
PMWS. These clinical signs include cachexia,
depression, respiratory distress and jaundice (Segales
and Domingo, 2002).
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To follow the degree of PCV2 replication in all
individual pigs, inguinal lymph node biopsies were
collected at different time points as described before
(Meerts et al., 2005c). At 10 dpi, a biopsy was taken
from the left inguinal lymph node and at 15 dpi, a
biopsy was taken from the right inguinal lymph node.
In order to take lymph node biopsies, the pigs were
anaesthetized by IM injection of 2.2 mg tiletamine and
2.2 mg zolazepam (Zoletil1, Virbac, Wavre, Bel-
gium) dissolved in 0.22 ml 2% xylazine (XYL-M1
2%, VMD, Arendonk, Belgium) kg1 body weight.
An incision was made in the overlaying skin and half
the inguinal lymph node was excised. The wound was
closed by mersilene sutures (Mersutures1, Ethicon,
USA). At the time of euthanasia (21 dpi) the
remaining parts of both left and right inguinal lymph
nodes were collected.
Ten % suspensions were made from these
biopsies and from the remaining parts of these
lymph nodes, and the level of PCV2 replication in
these organs was determined by PCV2 titration on
PK-15 cells. The detection limit of this technique
was 102.7 TCID50/g.
Quantification and immunophenotyping of PCV2
positive cells was performed on inguinal lymph node
biopsies that were collected at 15 dpi. Serial cryostat
sections were fixed in methanol at 20 8C for 10 min.
Double immunofluorescence stainings for CD4, CD8,
IgM or SWC3, respectively, and for PCV2, were
performed as described above. Prior to mounting,
autofluorescence was quenched by immersion of the
sections for 30 min in a 10 mM dilution of CuSo4 in a
50 mM NH4-acetate buffer at pH 5.0. PCV2 positive
cells were quantified and immunophenotyped using a
fluorescence microscope. The total number of PCV2
positive cells and the total number of double positive
cells (cell marker and PCV2) were determined over an
area of 10 mm2 of tissue.
2.6.4. Humoral immune response against PCV2
At 0, 7, 10, 15 and 21 dpi, blood was taken (1/1 in
Alsevers solution) from the jugular vein, in order to
monitor total anti-PCV2 Ab titres by an IPMA
described previously (Labarque et al., 2000). PCV2
neutralizing Abs were determined by a sensitive
neutralization assay described previously (Meerts
et al., 2005c).The animal experiments described in this study
were authorized and supervised by the Ethical and
Animal Welfare Committee of the Faculty of
Veterinary Medicine of Ghent University.
2.6.5. Statistical analysis
The statistical significance of differences between
non-treated pigs and ConA-treated pigs and between
non-treated pigs and rIFN-g-treated pigs was tested by
applying two-sided Kruskal–Wallis tests. Differences
were considered significant when p < 0.05. Statistical
analyses were performed using S-PLUS (S-PLUS 6.1,
Insightful Corporation, Seattle, USA, 2002).3. Results
3.1. In vitro experiments
3.1.1. PCV2 replication kinetics in PBMC
Fig. 1 demonstrates mean percentages of PCV2
positive cells and antigen expression patterns in
PCV2-inoculated PBMC of three conventional PCV2
seronegative pigs (pigs 1, 2 and 3). For strain 1121,
maximum numbers of antigen positive cells were very
low in non-treated PBMC (0.06% in pig 1 at 48 hpi,
0.14% in pig 2 at 72 hpi and 0.04% in pig 3 at 48 hpi).
Antigen positive cells were observed starting from
36 hpi (pigs 2 and 3) or 48 hpi (pig 1). In ConA-treated
PBMC, maximum numbers of antigen positive cells of
2.08%, 1.02% and 2.02% were observed at 96 hpi,
72 hpi and 96 hpi for pigs 1, 2 and 3, respectively.
Nuclear localized viral antigens were detected for the
first time at 12 hpi for pig 2 and at 36 hpi for pigs 1 and
3. Cytoplasmic localized viral antigens were detected
starting from 36 hpi. At this time point, 20–50% of
cells with viral antigens in the nucleus showed viral
antigens in the cytoplasm and all cells with viral
antigens in the cytoplasm showed viral antigens in the
nucleus. From 36 to 96 hpi, the numbers of total PCV2
antigen positive cells, positive cells with antigens in
the nucleus and positive cells with antigens in the
cytoplasm were significantly different in ConA-
treated PBMC when compared to non-treated PBMC.
In rIFN-g-treated PBMC, maximum numbers of
antigen positive cells were very low (0.06% in pig
1 at 72 hpi, 0.18% in pig 2 at 72 hpi and 0.06% in pig 3
at 36 and 48 hpi). Antigen positive cells were observed
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Fig. 1. Mean percentage (S.D.) of PCV2 antigen positive cells and
antigen expression patterns in non-treated, concanavalin A-treated
or recombinant interferon-gamma-treated, PCV2-inoculated PBMC
of three conventional PCV2 seronegative pigs at different time
points after in vitro inoculation of PBMC with strains 1121 and
Stoon-1010 (pigs 1, 2 and 3).starting from 24 hpi (pig 2), 36 hpi (pig 3) or 72 hpi
(pig 1).
For Stoon-1010, maximum numbers of antigen
positive cells were very low in non-treated PBMC
(0.02% in pig 1 at 96 hpi, 0.22% in pig 2 at 96 hpi and
0.00% in pig 3). Antigen positive cells were observed
starting from 12 hpi (pig 2) or 96 hpi (pig 1). In ConA-
treated PBMC, maximum numbers of antigen positive
cells of 0.96%, 0.84% and 0.34% were observed at
48 hpi for pig 1 and at 72 hpi for pigs 2 and 3,
respectively. Nuclear localized viral antigens were
detected for the first time at 24 hpi for pig 1 and at
12 hpi for pigs 2 and 3. Cytoplasmic localized viral
antigens were detected for the first time at 24 hpi for
pigs 1 and 2 and at 72 hpi for pig 3. At these timepoints, 12–33% of cells with viral antigens in the
nucleus showed viral antigens in the cytoplasm and all
cells with viral antigens in the cytoplasm showed viral
antigens in the nucleus. From 24 to 72 hpi, the
numbers of total PCV2 antigen positive cells and
positive cells with antigens in the nucleus were
significantly different in ConA-treated PBMC when
compared to non-treated PBMC. At 96 hpi, the
numbers of positive cells with antigens in the
cytoplasm were significantly different in ConA-
treated PBMC when compared to non-treated PBMC.
In rIFN-g-treated PBMC, maximum numbers of
antigen positive cells were very low (0.02% in pig
1 at 36 hpi, 0.16% in pig 2 at 72 hpi and 0.02% in pig 3
at 72 hpi). Antigen positive cells were observed
starting from 12 hpi (pig 2), 36 hpi (pig 1) or 72 hpi
(pig 3).
In ConA-treated PBMC, all cells with nuclear
localized capsid protein also contained Rep protein in
their nucleus. In 89% (1121) and 81% (Stoon-1010) of
the cells with nuclear localized Rep protein, nuclear
localized capsid protein was found. Cells with
cytoplasmic staining for capsid protein, without
nuclear staining for Rep or capsid proteins, were
observed starting from 48 hpi (pigs 2 and 3) or 72 hpi
(pig 1) for strain 1121 and starting from 48 hpi (pig 1),
72 hpi (pig 2) or 96 hpi (pig 3) for Stoon-1010. This
staining pattern was accompanied with morphological
changes typical for cellular degeneration. Rep protein
was never detected in the cytoplasm of PCV2 positive
cells, except in a small fraction of cells with typical
morphological signs of degeneration.
Positive reactions were not observed when staining
non-inoculated PBMC for PCV2 antigens or when
staining PCV2-inoculated PBMC with an irrelevant
isotype-matched mAb and with porcine PCV2-
negative control pAbs.
3.1.2. Identification of PCV2 positive PBMC
PBMC were obtained from three conventional
PCV2 seronegative pigs (pigs 4, 5 and 6). The
proportions of ConA-treated PCV2 positive PBMC
per cell smear, identified as CD4+, CD8+, IgM+ or
SWC3+ after inoculation with strain 1121, were
determined at 0, 36 and 72 hpi. At 0 hpi, PCV2
positive cells were not observed in ConA-treated
PBMC. At 36 hpi, PCV2 positive cells were identified
as CD4+ (48  5%), CD8+ (56  4%) and IgM+
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were CD4+, 54  11% were CD8+ and 11  4% were
IgM+. Viral antigen positive SWC3+ PBMC were not
found. The numbers of non-treated and rIFN-g-treated
PCV2 positive PBMC per cell smear were too low for
a correct interpretation of results.
3.1.3. Virus titration of PBMC culture
supernatant
Fig. 2 demonstrates the evolution of mean virus
titres in culture supernatants of PCV2-inoculated
PBMC of three conventional PCV2 seronegative pigs
(pigs 1, 2 and 3). Time-dependent rises in titres were
seen for supernatants of ConA-treated PBMC, starting
from 72 hpi for strain 1121 and from 48 hpi for Stoon-
1010. Maximum virus titres of 103.2 TCID50/ml
supernatant and 104.1 TCID50/ml supernatant were
observed for strain 1121 and Stoon-1010 at 96 hpi.
Significant differences between virus titres in super-
natants of non-treated PBMC and ConA-treated
PBMC were observed at 72 and 96 hpi for strainFig. 2. Evolution of mean (S.D.) PCV2 titres in culture super-
natants of non-treated, concanavalin A-treated or recombinant
interferon-gamma-treated, PCV2-inoculated PBMC of three con-
ventional PCV2 seronegative pigs (pigs 1, 2 and 3).1121 and at 36, 48 and 96 hpi for Stoon-1010. A small
but statistically significant difference between virus
titres in supernatants of non-treated PBMC and rIFN-
g-treated PBMC was observed for strain 1121 at
96 hpi.
3.2. In vivo experiments
3.2.1. Clinical monitoring
Clinical signs suggestive of PMWS were not
observed. Differences in general conditions were not
observed between any of the pigs. Inguinal lymph
nodes of all pigs of groups B (PCV2/ConA), C (PCV2/
rIFN-g), D (-/ConA) and E (-/rIFN-g) were noticeably
enlarged and pale. This was observed from the first
time a biopsy was taken, up to the end of the study.
Enlarged, pale inguinal lymph nodes were not
observed in any of the pigs of group A (PCV2-
inoculated, non-treated pigs). Pig 6 (group B, PCV2/
ConA) died during blood sampling at 15 dpi.
3.2.2. PCV2 replication
The evolution in PCV2 titres in the inguinal lymph
nodes of individual pigs is shown in Fig. 3. From all pigs
of groups A, B and C (PCV2-inoculated pigs), PCV2
was isolated at least at one time point. PCV2 could be
detected for the first time at 15 dpi in pigs of groups A
(PCV2/-) and C (PCV2/rIFN-g). In pigs of group B
(PCV2/ConA), PCV2 was already isolated from the
lymph node biopsies taken at 10 dpi. Titres at this time
point ranged between 103.0 and 104.3 TCID50/g. At 15
and 21 dpi, PCV2 titres in pigs of group B (PCV2/
ConA) were generally higher than in pigs of groups A
(PCV2/-) and C (PCV2/rIFN-g), but due to the high
variation in PCV2 titres between pigs in the same
groups and due to the limited number of pigs per group,
a significant difference between groups A (PCV2/-) and
B (PCV2/ConA) could only be observed at 10 dpi and
not at 15 and 21 dpi.
The general evolution in PCV2 titres in time was
similar in all pigs from groups A, B and C (PCV2-
inoculated pigs), except in one pig (pig 7) from group
B (PCV2/ConA). Eleven out of twelve pigs of groups
A, B and C (PCV2-inoculated pigs) showed a peak of
PCV2 replication at 15 dpi. Afterwards, the PCV2
titres decreased in all these pigs. Pig 7 (group B,
PCV2/ConA) showed a gradual increase in PCV2 titre
until the end of the study.
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Fig. 3. Evolution of PCV2 titres in inguinal lymph nodes of PCV2-inoculated caesarean-derived colostrum-deprived pigs of groups A (non-
treated), B (treated with concanavalin A, ConA) and C (treated with recombinant interferon-gamma, rIFN-g), and of non-inoculated pigs of
groups D (treated with concanavalin A, ConA) and E (treated with recombinant interferon-gamma, rIFN-g). The dashed line represents the
detection limit of the assay (102.7 TCID50/g).In pigs of groups D and E (non-inoculated pigs),
PCV2 was never isolated during the study.
Table 2 shows the results of the quantification and
immunophenotyping of PCV2 positive cells in
inguinal lymph node biopsies at 15 dpi. In biopsies
from pigs of groups A (PCV2/-) and C (PCV2/rIFN-
g), low numbers of PCV2 positive cells were observed
(less than 20 PCV2 positive cells per 10 mm2). In
these pigs, PCV2 was mainly localized in SWC3+
cells, but in some pigs small proportions of PCV2
positive cells were CD4+, CD8+ or IgM+. PCV2
positive cells were mainly observed as single cells in
follicular and parafollicular regions.
The number of PCV2 positive cells was signifi-
cantly higher in biopsies from group B (PCV2/ConA)
pigs 5, 6 and 7 (389–664 PCV2 positive cells per
10 mm2), when compared to pigs from group A
(PCV2/-). In pigs 5, 6 and 7, PCV2 was found in
CD4+, CD8+, IgM+ and SWC3+ cells. In pigs 6 and 7,
SWC3+ cells were the predominantly PCV2 positive
cell type (75% and 66%, respectively). In pig 5, the
percentages of CD4+, CD8+, IgM+ and SWC3+ PCV2positive cells ranged from 14% to 33%. In pigs 5, 6
and 7, the vast majority of PCV2 positive cells were
located in the peripheral areas of the follicular regions
and in the parafollicular regions. In these pigs, PCV2
antigens were occasionally (<5%) observed in the
nucleus of CD4+, CD8+, IgM+ and SWC3+ cells. For
pig 8 (group B, PCV2/ConA), similar observations
were made as for pigs from groups A (PCV2/-) and C
(PCV2/rIFN-g).
PCV2 positive cells were not observed in any of the
pigs of groups D and E (non-inoculated pigs).
3.2.3. Humoral immune response against PCV2
The evolution in PCV2-specific Abs, as demon-
strated by IPMA, is shown in Fig. 4. Anti-PCV2 Abs
were demonstrated in all pigs from groups A, B and
C (PCV2-inoculated pigs), except in the pig that
died at 15 dpi (pig 6, group B, PCV2/ConA).
Differences were observed in the time points at
which anti-PCV2 Abs were detected for the first
time. Pigs from group A (PCV2/-) seroconverted at
10 or 15 dpi. In groups B (PCV2/ConA) and C
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Table 2
Quantification and immunophenotyping of PCV2 positive cells at 15 days post-inoculation in inguinal lymph node biopsies of PCV2-inoculated
caesarean-derived colostrum-deprived pigs of groups A (non-treated), B (treated with concanavalin A, ConA) and C (treated with recombinant
interferon-gamma, rIFN-g)
Group Pig no. Treatment Virus titre
(log 10 TCID50/g)
Identification of PCV2 positive cells asa
CD4+ CD8+ IgM+ SWC3+
A 1 – 3.3 2/9 (22%) 1/5 (20%) 1/5 (20%) 5/7 (71%)
2 – 3.3 0/4 (0%) 0/10 (0%) 0/2 (0%) 1/1 (100%)
3 – 5.8 4/18 (22%) 0/13 (0%) 3/10 (30%) 7/11 (64%)
4 – 3.0 0/2 (0%) 0/2 (0%) 0/4 (0%) 1/1 (100%)
B 5 ConA 4.5 140/434 (32%) 60/432 (14%) 89/389 (23%) 136/418 (33%)
6 ConA 5.0 77/635 (12%) 69/664 (10%) 70/555 (13%) 339/454 (75%)
7 ConA 6.3 72/570 (13%) 84/555 (15%) 44/537 (8%) 394/601 (66%)
8 ConA 4.0 0/4 (0%) 0/5 (0%) 0/1 (0%) 4/4 (100%)
C 9 rIFN-g 3.0 1/8 (13%) 0/4 (0%) 0/7 (0%) 12/16 (75%)
10 rIFN-g 3.3 0/2 (0%) 0/1 (0%) 0/2 (0%) 1/2 (50%)
11 rIFN-g 3.3 0/1 (0%) 0/2 (0%) 0/1 (0%) 2/2 (100%)
12 rIFN-g 3.5 1/10 (10%) 1/2 (50%) 0/6 (0%) 10/15 (67%)
Pigs from groups D and E (non-inoculated pigs) did not have PCV2 positive cells.
a Number of both PCV2 and cell marker positive cells/total number of PCV2 positive cells per 10 mm2 tissue.(PCV2/rIFN-g), only 2 out of 4 pigs seroconverted
at 15 dpi. In the other pigs of groups B (PCV2/
ConA) and C (PCV2/rIFN-g), seroconversion
against the virus was delayed until 21 dpi. Statis-
tically significant differences were not detected atFig. 4. Evolution of anti-PCV2 antibody titres (IPMA) in PCV2-inocula
treated), B (treated with concanavalin A, ConA) and C (treated with reco
groups D (treated with concanavalin A, ConA) and E (treated with recomany of the time points. PCV2 neutralizing Abs
evolved in a similar way as PCV2-specific Abs
detected by IPMA (data not shown). None of the
pigs from groups D or E (non-inoculated pigs)
seroconverted against PCV2.ted caesarean-derived colostrum-deprived pigs of groups A (non-
mbinant interferon-gamma, rIFN-g), and in non-inoculated pigs of
binant interferon-gamma, rIFN-g).
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In the present study, it was shown that the mitogen
ConA increases PCV2 replication in porcine leuko-
cytes both in vitro and in vivo. An effect of rIFN-g on
PCV2 replication in leukocytes was not observed
under the conditions of the present study. Expression
of PCV2 antigens in ConA-stimulated PBMC was
observed starting from 12 to 36 hpi, depending on the
PCV2 strain and the blood donor that were used. This
is in agreement with another study, in which PCV2
replication was observed in ConA-stimulated PBMC
from 18 hpi onwards (Yu et al., 2007). In the present
study, the first detectable viral antigens were localized
in the nucleus. These antigens were identified as Rep
proteins and capsid proteins. This suggests that in the
early stages of infection, newly synthesized Rep and
capsid proteins are efficiently transported to the
nucleus where genome replication and encapsidation
take place. As infection progressed, the number of
cells with capsid proteins in the cytoplasm increased,
suggesting the translocation of assembled virions from
the nucleus to the cytoplasm, as suggested previously
by Finsterbusch et al. (2005). At the late stages of
infection, cells with intense cytoplasmic staining but
without nuclear staining were observed. This was
accompanied with morphological changes typical for
cellular degeneration, suggesting that PCV2 infection
may lead to cell death. Only in these degenerated cells,
the Rep protein was occasionally found in the
cytoplasm, indicating a very strong affinity of the
Rep protein for the nucleus in viable cells. The results
further suggest that the rise in PCV2 titres in culture
supernatants coincided with the appearance of these
degenerated cells. The fact that PCV2 antigens were
most frequently found in the nucleus of PBMC early in
replication contradicts with earlier findings in PK-15
cells. The majority of PCV2-infected PK-15 cells have
capsid antigens in the cytoplasm without having Rep
or capsid antigens in the nucleus during the early
stages of the replication cycle (Meerts et al., 2005a).
Since it is known that cellular transcription factors of
lymphoid and epithelial cell types can have different
specificities for promoters, enhancers and co-activa-
tors (Foster et al., 1985; Forsberg and Westin, 1991), it
can be speculated that in PK-15 cells the RNA
polymerase II transcription-initiation complex might
have a higher affinity for the promoter region of thecapsid gene than for the promoter region of the Rep
gene, leading to expression of the capsid protein in a
large number of cells without expression of the Rep
protein. In ConA-treated PBMC, the affinities of this
complex for both promoters may be equal, leading to a
simultaneous expression of the Rep protein and the
capsid protein.
In the present study, it was demonstrated that PCV2
replicates in CD4+, CD8+ and IgM+ PBMC, suggest-
ing that not only circulating T-lymphocytes, which
was demonstrated previously by Yu et al. (2007), but
also circulating B-lymphocytes may be susceptible to
PCV2 replication in vitro. Since CD4 is also present on
e.g. natural IFN-a producing cells (Charley and
Lavenant, 1990) and since CD8 is also present on e.g.
natural killer cells (Saalmuller et al., 1994), we cannot
exclude the possibility that in vitro stimulation with
ConA makes these cell types susceptible to PCV2
replication as well. Further research should clarify this
issue. As in other in vitro studies (Yu et al., 2007), we
failed to demonstrate PCV2 replication in PBMC-
derived monocytes.
Meerts et al. (2005b) have previously shown that
IFN-g enhances PCV2 replication in vitro in porcine
epithelial and monocytic cell lines. This enhancing
effect by IFN-g was caused by an increased
internalization of bound virions into the cell. The
influence of IFN-g on the internalization of PCV2 in
PBMC was not investigated in the present study. In
cell lines, active cellular polymerases allow PCV2 to
complete its infectious cycle. Therefore, we assume
that the enhancing effect of ConA on PCV2 replication
in PBMC in vitro was merely due to its high mitotic
activity. We assume that the lack of high mitotic
activity of rIFN-g, under the conditions of the present
study, was the main reason why rIFN-g did not have an
effect on PCV2 replication in PBMC in vitro.
In preliminary experiments, PCV2 replication was
also observed in PBMC stimulated with phytohae-
magglutinin and a combination of ionomycin and
phorbol dibutyrate but not with LPS (data not shown).
The best results were obtained with ConA and
therefore this mitogen was selected for the present
study. The technique that has been described is
inexpensive, easy to perform and therefore it is
potentially suitable for detailed in vitro studies of the
PCV2 replication cycle in lymphocytes, studies that
are nowadays merely performed in cell lines.
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CD/CD pigs with ConA renders them more susceptible
to an increased PCV2 replication. Injecting the pigs
with rIFN-g, following the protocol that was used in the
present study, could not induce this increased PCV2
replication. The different outcomes of the ConA and
rIFN-g treatments could be due to various mechanisms.
ConA is known to cause proliferation and activation of
mainly T-lymphocytes (Mosmann et al., 1986), but it
also affects other immune cell types such as B-
lymphocytes (Andersson et al., 1972) and monocytes/
macrophages (Smith and Goldman, 1972). ConA also
induces various cytokines and IFN-g is just one of them.
ConA thus has a much wider range of biological
activities than IFN-g. ConA also induces much higher
concentrations and a more prolonged production of
IFN-g in animals compared to the IFN-g concentration
that can be reached by injecting rIFN-g. Injected rIFN-g
is very quickly removed from the body (Lortat-Jacob
et al., 1996), while ConA induces a continuous
production of IFN-g by the T-lymphocytes of the
animal. Unfortunately, we were not able to demonstrate
the presence of IFN-g in plasma samples of the CD/CD
pigs of the present study, nor with a bio-assay on PK-15
cells, nor with a commercial ELISA for IFN-g
(Biosource Europe, Nivelles, Belgium), indicating that
IFN-g blood levels were very low at the times of blood
sampling (data not shown). Nevertheless, the treatments
of pigs with ConA or rIFN-g were effective since
inguinal lymph nodes of treated pigs were clearly
enlarged, whether these pigs were inoculated with
PCV2 or not. Therefore, results from the present study
are indicative that the enhancing effect of ConA
treatment on PCV2 replication was due to the global
effect of ConA on the pig’s immune system and not to
the effect of IFN-g alone. Obviously, more research
needs to be performed to address this issue.
A remarkable difference between ConA-treated
pigs and non-treated and rIFN-g-treated pigs was
observed in inguinal lymph node biopsies collected at
15 dpi. High numbers of PCV2-infected cells were
observed in 3 out of 4 ConA-treated pigs. PCV2-
infected cells were identified as CD4+, CD8+, IgM+
and SWC3+, as demonstrated previously by Sanchez
et al. (2004). Although PCV2 replicated to high levels
in cells of the immune system, only 2 of these 3 pigs
showed a delayed onset of the humoral immune
response against PCV2. High levels of PCV2replication in cells of the immune system were not
observed in non-treated and rIFN-g-treated pigs. Still,
a delayed onset of the humoral immune response was
observed in 2 out of 4 rIFN-g-injected pigs. This
suggests that the delayed humoral immune response
observed in 2 out of 4 ConA-treated and in 2 out of 4
rIFN-g-treated pigs was not caused by high levels of
PCV2 replication in cells of the immune system, but
might have been caused by a common effect of ConA
and rIFN-g treatments in these specific pigs. Possible
responsible mechanisms include the inhibitory effects
of ConA-activated suppressor T-cells on B-cell
proliferation and antibody production (Redelman
et al., 1976), and the inhibitory effect of IFN-g on
the early stages of B-cell activation (Abed et al.,
1994). The present results further suggest that an
impaired humoral immune response against PCV2 is
not sufficient to cause high levels of PCV2 replication.
Further research should deal with these issues.
In the present study, it was again demonstrated that
it can be difficult to reproduce PCV2-associated
disease in CD/CD pigs. Even in the ConA-treated pigs
that experienced an increased PCV2 replication,
clinical signs were not observed. Still, the ConA
treatment might provide a valuable tool to investigate
the link between high PCV2 replication and PMWS.
Several treatments of CD/CD pigs that influence the
pig’s immune system have been described until now. It
has been demonstrated that immune stimulation
(Krakowka et al., 2001), immune suppression by
Cyclosporin A (Meerts et al., 2005c) and mitogen
treatment (the present study) are able to increase
PCV2 replication in pigs. This observation may
indicate that there is an unstable equilibrium between
a specific immune response that is able to neutralize
PCV2 and to eliminate PCV2-infected cells, and an
immune response that facilitates the replication of the
virus in the pig. This fragile balance might be the
underlying mechanism responsible for the high
variation that is observed in PCV2 replication and
clinical outcome between individual pigs and the even
higher variation between different studies.Acknowledgements
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